HUE061615T2 - Foszfoinozitid-3-kináz gátlószereit és második antiproliferatív hatóanyagot tartalmazó készítmények - Google Patents
Foszfoinozitid-3-kináz gátlószereit és második antiproliferatív hatóanyagot tartalmazó készítményekInfo
- Publication number
- HUE061615T2 HUE061615T2 HUE16756763A HUE16756763A HUE061615T2 HU E061615 T2 HUE061615 T2 HU E061615T2 HU E16756763 A HUE16756763 A HU E16756763A HU E16756763 A HUE16756763 A HU E16756763A HU E061615 T2 HUE061615 T2 HU E061615T2
- Authority
- HU
- Hungary
- Prior art keywords
- kinase inhibitors
- preparations containing
- antiproliferative agent
- phosphoinositide
- containing phosphoinositide
- Prior art date
Links
- 230000001028 anti-proliverative effect Effects 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 title 1
- 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 title 1
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1514760.6A GB201514760D0 (en) | 2015-08-19 | 2015-08-19 | Compounds and method of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE061615T2 true HUE061615T2 (hu) | 2023-07-28 |
Family
ID=54258859
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE16756763A HUE061615T2 (hu) | 2015-08-19 | 2016-08-19 | Foszfoinozitid-3-kináz gátlószereit és második antiproliferatív hatóanyagot tartalmazó készítmények |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US10668077B2 (https=) |
| EP (1) | EP3337477B1 (https=) |
| JP (1) | JP2018523689A (https=) |
| KR (1) | KR20180064387A (https=) |
| CN (2) | CN113786409B (https=) |
| AU (1) | AU2016307885B2 (https=) |
| CA (1) | CA2995898A1 (https=) |
| DK (1) | DK3337477T3 (https=) |
| ES (1) | ES2939815T3 (https=) |
| FI (1) | FI3337477T3 (https=) |
| GB (1) | GB201514760D0 (https=) |
| HR (1) | HRP20230376T1 (https=) |
| HU (1) | HUE061615T2 (https=) |
| IL (1) | IL257499A (https=) |
| LT (1) | LT3337477T (https=) |
| MX (1) | MX2018001926A (https=) |
| PL (1) | PL3337477T3 (https=) |
| PT (1) | PT3337477T (https=) |
| RS (1) | RS64095B1 (https=) |
| SI (1) | SI3337477T1 (https=) |
| SM (1) | SMT202300063T1 (https=) |
| WO (1) | WO2017029517A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN2012DN01325A (https=) | 2009-08-20 | 2015-06-05 | Karus Therapeutics Ltd | |
| GB201204125D0 (en) | 2012-03-08 | 2012-04-25 | Karus Therapeutics Ltd | Compounds |
| GB201402431D0 (en) | 2014-02-12 | 2014-03-26 | Karus Therapeutics Ltd | Compounds |
| ES2863500T3 (es) | 2015-04-10 | 2021-10-11 | Capsugel Belgium Nv | Formulaciones lipídicas de acetato de abiraterona |
| GB201514760D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds and method of use |
| GB201514751D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds |
| GB201514758D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Formulation |
| GB201514754D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds |
| SG11202102343QA (en) * | 2018-09-11 | 2021-04-29 | Curis Inc | Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety |
| JPWO2020059705A1 (ja) * | 2018-09-18 | 2021-08-30 | 株式会社ヤクルト本社 | キノリンカルボキサミド誘導体を用いるがん併用療法 |
| PT3930715T (pt) * | 2019-02-27 | 2024-08-02 | Astrazeneca Ab | Saracatinib para uso no tratamento de fibrose pulmonar idiopática |
| CN111904958B (zh) * | 2019-05-09 | 2022-09-13 | 浙江大学 | Umi-77作为线粒体自噬诱导剂在制备治疗炎症及神经退行性疾病药物中的应用 |
| GB201909468D0 (en) * | 2019-07-01 | 2019-08-14 | Karus Therapeutics Ltd | Compounds for treating cancer |
| WO2022105836A1 (en) * | 2020-11-19 | 2022-05-27 | Guangzhou Healthquest Pharma Co., Ltd. | Combination therapies for treating cancer |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1445742A1 (de) | 1963-11-06 | 1968-12-19 | Bayer Ag | Verfahren zur Herstellung von 2-Stellung substituierten Benzoxazinonen |
| US4017500A (en) | 1973-07-16 | 1977-04-12 | Schering Corporation | Certain 8-amino-1,7-naphthyridines |
| BE786081A (fr) * | 1971-07-13 | 1973-01-10 | Uniroyal Sa | Appareil et procede pour maintenir les tringles des bourrelets de pneu |
| US5703075A (en) | 1988-12-21 | 1997-12-30 | Pharmacia & Upjohn Company | Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones |
| CN1250294A (zh) * | 1999-07-27 | 2000-04-12 | 邮电部武汉邮电科学研究院 | 以太网与同步数字体系或同步光网络融合的适配方法 |
| EA004872B1 (ru) | 1999-08-03 | 2004-08-26 | ЛИЛЛИ АЙКОС эЛ-эЛ-Си | β-КАРБОЛИНОВЫЕ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ |
| CN1186324C (zh) | 2000-04-27 | 2005-01-26 | 山之内制药株式会社 | 稠合杂芳基衍生物 |
| US6608053B2 (en) | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
| JP2004502686A (ja) | 2000-06-30 | 2004-01-29 | スージェン・インコーポレーテッド | ４−ヘテロアリール−３−ヘテロアリーリデニル−２−インドリノンおよび蛋白質キナーゼ阻害剤としてのその使用 |
| US6905669B2 (en) | 2001-04-24 | 2005-06-14 | Supergen, Inc. | Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase |
| EP2280003B1 (en) | 2002-07-15 | 2014-04-02 | Symphony Evolution, Inc. | Process for preparing receptor-type kinase modulators |
| FR2846657B1 (fr) | 2002-11-05 | 2004-12-24 | Servier Lab | Nouveaux composes pyridopyrimidinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| WO2005082887A1 (ja) | 2004-02-26 | 2005-09-09 | Aska Pharmaceutical Co., Ltd. | ピリミジン誘導体 |
| JP2008500338A (ja) | 2004-05-25 | 2008-01-10 | イコス・コーポレイション | 造血細胞の異常増殖を治療及び／又は予防する方法 |
| GB0423653D0 (en) | 2004-10-25 | 2004-11-24 | Piramed Ltd | Pharmaceutical compounds |
| WO2006127587A1 (en) | 2005-05-20 | 2006-11-30 | Vertex Pharmaceuticals Incorporated | Pyrrolopyridines useful as inhibitors of protein kinase |
| US20070208053A1 (en) | 2006-01-19 | 2007-09-06 | Arnold Lee D | Fused heterobicyclic kinase inhibitors |
| RU2008141356A (ru) | 2006-04-26 | 2010-06-10 | Ф. Хоффманн-Ля Рош Аг (Ch) | Производные пиримидина в качестве ингибиторов фосфатидилинозитол-3-киназы (pi3k) |
| CN101511840A (zh) | 2006-04-26 | 2009-08-19 | 吉宁特有限公司 | 磷酸肌醇3-激酶抑制剂化合物及其使用方法 |
| ES2365258T3 (es) | 2006-06-26 | 2011-09-27 | Ucb Pharma S.A. | Derivados de tiazol condensados como inhibidores de quinasa. |
| UA97483C2 (ru) * | 2006-08-08 | 2012-02-27 | Чугай Сейяку Кабушики Кайша | Производное пиримидина в качестве ингибитора pi3k и его применение |
| KR20090087027A (ko) | 2006-11-13 | 2009-08-14 | 일라이 릴리 앤드 캄파니 | 염증 질환 및 암의 치료를 위한 티에노피리미디논 |
| EP2120909A2 (en) | 2006-12-15 | 2009-11-25 | Ordway Research Institute | Treatments of therapy-resistant diseases comprising drug combinations |
| AU2008210455A1 (en) | 2007-01-31 | 2008-08-07 | Vertex Pharmaceuticals Incorporated | 2-aminopyridine derivatives useful as kinase inhibitors |
| US20100063032A1 (en) | 2007-03-28 | 2010-03-11 | Debenham John S | Substituted pyrido[2,3-d]pyrimidine derivatives as cannabinoid-1 receptor modulators |
| WO2008150827A1 (en) | 2007-05-29 | 2008-12-11 | Smithkline Beecham Corporation | Naphthyridine, derivatives as p13 kinase inhibitors |
| GB0710528D0 (en) | 2007-06-01 | 2007-07-11 | Glaxo Group Ltd | Novel compounds |
| AU2008298948B2 (en) * | 2007-09-12 | 2014-09-04 | F. Hoffmann-La Roche Ag | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use |
| JP2011529932A (ja) | 2008-08-05 | 2011-12-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 置換ナフチリジン及び医薬としてのその使用 |
| CA2742550A1 (en) | 2008-10-03 | 2010-04-08 | Merck Serono S.A. | 4-morpholino-pyrido[3,2-d]pyrimidines |
| GB2465405A (en) | 2008-11-10 | 2010-05-19 | Univ Basel | Triazine, pyrimidine and pyridine analogues and their use in therapy |
| WO2011012883A1 (en) | 2009-07-29 | 2011-02-03 | Karus Therapeutics Limited | Benzo [e] [1, 3 ] oxazin-4-one derivatives as phosphoinositide 3-kinase inhibitors |
| IN2012DN01325A (https=) * | 2009-08-20 | 2015-06-05 | Karus Therapeutics Ltd | |
| US20110207736A1 (en) | 2009-12-23 | 2011-08-25 | Gatekeeper Pharmaceuticals, Inc. | Compounds that modulate egfr activity and methods for treating or preventing conditions therewith |
| GB201007347D0 (en) | 2010-04-30 | 2010-06-16 | Karus Therapeutics Ltd | Compounds |
| CN101849934B (zh) * | 2010-05-25 | 2011-11-09 | 苏州大学 | 一种磷脂酰肌醇-3-激酶抑制剂及其应用 |
| EP2518070A1 (en) | 2011-04-29 | 2012-10-31 | Almirall, S.A. | Pyrrolotriazinone derivatives as PI3K inhibitors |
| CN103702990B (zh) | 2011-07-27 | 2015-09-09 | 阿斯利康(瑞典)有限公司 | 2-(2,4,5-取代苯胺)嘧啶衍生物作为egfr调谐子用于治疗癌症 |
| WO2013017480A1 (en) | 2011-07-29 | 2013-02-07 | Cellzome Limited | Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors |
| GB201204125D0 (en) | 2012-03-08 | 2012-04-25 | Karus Therapeutics Ltd | Compounds |
| RU2015118647A (ru) | 2012-11-20 | 2017-01-10 | Дженентек, Инк. | Аминопиримидиновые соединения в качестве ингибиторов содержащих т790м мутантных egfr |
| NZ714283A (en) | 2013-05-10 | 2020-04-24 | Karus Therapeutics Ltd | Novel histone deacetylase inhibitors |
| SG11201509842SA (en) * | 2013-05-30 | 2015-12-30 | Infinity Pharmaceuticals Inc | Treatment of cancers using pi3 kinase isoform modulators |
| WO2014210354A1 (en) | 2013-06-28 | 2014-12-31 | Genentech, Inc. | Azaindazole compounds as inhibitors of t790m containing egfr mutants |
| ES2929576T3 (es) | 2013-10-08 | 2022-11-30 | Acetylon Pharmaceuticals Inc | Combinaciones de inhibidores de histona deacetilasa 6 y el inhibidor de Her2 lapatinib para el uso en el tratamiento del cáncer de mama |
| US20150105383A1 (en) | 2013-10-10 | 2015-04-16 | Acetylon Pharmaceuticals, Inc. | HDAC Inhibitors, Alone Or In Combination With PI3K Inhibitors, For Treating Non-Hodgkin's Lymphoma |
| GB201321728D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321730D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321738D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
| GB201321729D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201402431D0 (en) | 2014-02-12 | 2014-03-26 | Karus Therapeutics Ltd | Compounds |
| MA40933A (fr) | 2014-11-11 | 2017-09-19 | Piqur Therapeutics Ag | Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines |
| GB201514760D0 (en) * | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds and method of use |
| GB201514754D0 (en) * | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds |
| GB201514756D0 (en) * | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compound and method of use |
| GB201514751D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds |
| GB201514758D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Formulation |
| GB201909468D0 (en) | 2019-07-01 | 2019-08-14 | Karus Therapeutics Ltd | Compounds for treating cancer |
-
2015
- 2015-08-19 GB GBGB1514760.6A patent/GB201514760D0/en not_active Ceased
-
2016
- 2016-08-19 RS RS20230255A patent/RS64095B1/sr unknown
- 2016-08-19 MX MX2018001926A patent/MX2018001926A/es unknown
- 2016-08-19 DK DK16756763.5T patent/DK3337477T3/da active
- 2016-08-19 CN CN202111104917.2A patent/CN113786409B/zh active Active
- 2016-08-19 CA CA2995898A patent/CA2995898A1/en not_active Abandoned
- 2016-08-19 PT PT167567635T patent/PT3337477T/pt unknown
- 2016-08-19 PL PL16756763.5T patent/PL3337477T3/pl unknown
- 2016-08-19 US US15/753,353 patent/US10668077B2/en active Active
- 2016-08-19 FI FIEP16756763.5T patent/FI3337477T3/fi active
- 2016-08-19 HR HRP20230376TT patent/HRP20230376T1/hr unknown
- 2016-08-19 KR KR1020187007564A patent/KR20180064387A/ko not_active Withdrawn
- 2016-08-19 CN CN201680057437.6A patent/CN108348505B/zh active Active
- 2016-08-19 AU AU2016307885A patent/AU2016307885B2/en not_active Ceased
- 2016-08-19 LT LTEPPCT/GB2016/052575T patent/LT3337477T/lt unknown
- 2016-08-19 SM SM20230063T patent/SMT202300063T1/it unknown
- 2016-08-19 JP JP2018508757A patent/JP2018523689A/ja not_active Withdrawn
- 2016-08-19 EP EP16756763.5A patent/EP3337477B1/en active Active
- 2016-08-19 SI SI201631666T patent/SI3337477T1/sl unknown
- 2016-08-19 WO PCT/GB2016/052575 patent/WO2017029517A1/en not_active Ceased
- 2016-08-19 ES ES16756763T patent/ES2939815T3/es active Active
- 2016-08-19 HU HUE16756763A patent/HUE061615T2/hu unknown
-
2018
- 2018-02-13 IL IL257499A patent/IL257499A/en unknown
-
2020
- 2020-04-22 US US16/855,758 patent/US11291669B2/en active Active
-
2022
- 2022-03-01 US US17/684,020 patent/US12257254B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| DK3337477T3 (en) | 2023-02-20 |
| HK1251467A1 (en) | 2019-02-01 |
| US20230066999A1 (en) | 2023-03-02 |
| SMT202300063T1 (it) | 2023-03-17 |
| IL257499A (en) | 2018-07-31 |
| CN108348505B (zh) | 2021-10-12 |
| US12257254B2 (en) | 2025-03-25 |
| KR20180064387A (ko) | 2018-06-14 |
| HRP20230376T1 (hr) | 2023-06-23 |
| AU2016307885B2 (en) | 2019-07-25 |
| EP3337477B1 (en) | 2023-02-01 |
| US20210069200A1 (en) | 2021-03-11 |
| PT3337477T (pt) | 2023-03-20 |
| US10668077B2 (en) | 2020-06-02 |
| CN113786409B (zh) | 2024-04-02 |
| US11291669B2 (en) | 2022-04-05 |
| JP2018523689A (ja) | 2018-08-23 |
| WO2017029517A1 (en) | 2017-02-23 |
| GB201514760D0 (en) | 2015-09-30 |
| CN113786409A (zh) | 2021-12-14 |
| CA2995898A1 (en) | 2017-02-23 |
| US20180243313A1 (en) | 2018-08-30 |
| FI3337477T3 (fi) | 2023-04-27 |
| CN108348505A (zh) | 2018-07-31 |
| MX2018001926A (es) | 2018-06-19 |
| SI3337477T1 (sl) | 2023-04-28 |
| PL3337477T3 (pl) | 2023-07-03 |
| RS64095B1 (sr) | 2023-04-28 |
| LT3337477T (lt) | 2023-03-10 |
| AU2016307885A1 (en) | 2018-03-08 |
| EP3337477A1 (en) | 2018-06-27 |
| ES2939815T3 (es) | 2023-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE061615T2 (hu) | Foszfoinozitid-3-kináz gátlószereit és második antiproliferatív hatóanyagot tartalmazó készítmények | |
| IL259766B (en) | Relocalization systems and methods | |
| IL289276A (en) | Treprostinil derivatives and compositions and uses thereof | |
| HUE054159T2 (hu) | HPK1 gátlók és azok alkalmazási módja | |
| IL280863A (en) | Autotaxin inhibitors and uses thereof | |
| DK3448386T3 (da) | Isoquinolin-3-ylcarboxamider og fremstilling og anvendelse deraf | |
| HUE039919T2 (hu) | Mozgatható patronos aeroszolkijuttató eszköz és annak összeszerelési eljárása | |
| DK3452463T3 (da) | Amidsubstituerede pyridinyltriazolderivater og anvendelser deraf | |
| HUE055755T2 (hu) | Szulfonolkarmabidok és rokon vegyületeik valamint felhasználásuk | |
| DK3357513T3 (da) | Farmaceutisk sammensætning og anvendelse deraf | |
| DK3234151T3 (da) | Systemer til svampegenommodificering og fremgangsmåder til anvendelse deraf | |
| DK3205650T3 (da) | Egfr-hæmmer og fremstilling og anvendelse deraf | |
| DK3210977T3 (da) | Hidtil ukendt aminoalkylbenzothiazepinderivat og anvendelse deraf | |
| DK3672976T3 (da) | Bcl-2-hæmmere | |
| HUE055473T2 (hu) | Difluormetil-aminopiridinek és difluormetil-aminopirimidinek | |
| DK3395801T3 (da) | Arylazolforbindelse og skadedyrsbekæmpelsesmiddel | |
| DK3543240T3 (da) | URAT1-inhibitor og anvendelse deraf | |
| HUE063120T2 (hu) | LRRC33-inhibitorok és alkalmazásuk | |
| DK3256598T3 (da) | Svampestammer og anvendelsesfremgangsmåder | |
| HUE060805T2 (hu) | Piridinamin-piridon és pirimidinamin-piridon vegyületek | |
| HUE049409T2 (hu) | Alkinilpiridin-prolil-hidroxiláz inhibitor és annak elõállítási eljárása és gyógyászati alkalmazása | |
| DK3321279T3 (da) | Exenatidmodificeringsmiddel og anvendelse deraf | |
| DK3142659T3 (da) | Hiv-1 proteasehæmmere og anvendelser deraf | |
| HUE066987T2 (hu) | Szelektív il-6-transz-szignalizációt gátló szert tartalmazó készítmények | |
| DK3365321T3 (da) | Solabegron-zwitterion og anvendelser deraf |